Jaswinder Banga is a 26-year-old young man who was stopped in his tracks with a sudden diagnosis of the debilitating ankylosing spondylitis. While waiting for his critical surgery, he shares his travails since the diagnosis.
Please tell us about your present condition. Can you describe it?
My present condition is that I am confined to the wheelchair and completely bedridden for the last 3 to 3 and a half years due to severe deformity in hips and knees. Also, my legs are intertwined. This is…

Tofacitinib (Xeljanz®) is the first of a unique class of oral kinase inhibitors to be FDA approved for the treatment of rheumatoid arthritis (RA). Tofacitinib is a selective inhibitor of Janus kinase (JAK) enzymes. these enzymes mediate signaling for several important cytokines that cause the inflammation in Rheumatoid Arthritic patients.
Changed
06/Sep/2014
Condition